Search Results - "Tomioka, Nobumoto"

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) by Tomioka, Nobumoto, Azuma, Manabu, Ikarashi, Mayuko, Yamamoto, Mitsugu, Sato, Masako, Watanabe, Ken-ichi, Yamashiro, Katsushige, Takahashi, Masato

“…Background The status of tumor-infiltrating lymphocytes (TILs) is a prognostic factor for triple negative breast cancer (TNBC). Recent studies have shown that…”
Get full text

Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients by Takada, Shinya, Maeda, Hideki, Umehara, Kengo, Kuwahara, Sayuri, Yamamoto, Mitsugu, Tomioka, Nobumoto, Watanabe, Kenichi, Mino, Kozo

“…Therapy for patients of metastatic breast cancer based on palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has been approved in Japan. However, the risk…”
Get full text

Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer by Minoura, Yuko, Takahashi, Masato, Maeda, Hideki, Kuwahara, Sayuri, Tachikawa, Hanae, Yamamoto, Mitsugu, Tomioka, Nobumoto, Watanabe, Kenichi, Sakurai, Akihiro

“…Background When considering BRCA1/2 genetic testing for diagnosis of hereditary breast and ovarian cancer (HBOC), family history (FH) of breast and ovarian…”
Get full text

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer by Yamashita, Hiroko, Ogiya, Akiko, Shien, Tadahiko, Horimoto, Yoshiya, Masuda, Norikazu, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Endo, Yumi, Hosoda, Mitsuchika, Ishida, Naoko, Horii, Rie, Yamazaki, Kieko, Miyoshi, Yuichiro, Yasojima, Hiroyuki, Tomioka, Nobumoto

“…Background Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who received tamoxifen or aromatase…”
Get full text

Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region by Tomioka, Nobumoto, Hatanaka, Kanako C., Okuyama, Dai, Watanabe, Ken-ichi, Yamamoto, Mitsugu, Maeda, Hideki, Tachikawa, Hanae, Kuwahara, Sayuri, Shimizu, Ai, Suzuki, Hiroaki, Hatanaka, Yutaka, Takahashi, Masato

“…Background The efficacy of pre-operative systemic treatment (PST) combined with immune checkpoint inhibition (ICI) for triple-negative breast cancer (TNBC) has…”
Get full text

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial) by Masuda, Jun, Sakai, Hitomi, Tsurutani, Junji, Tanabe, Yuko, Masuda, Norikazu, Iwasa, Tsutomu, Takahashi, Masato, Futamura, Manabu, Matsumoto, Koji, Aogi, Kenjiro, Iwata, Hiroji, Hosonaga, Mari, Mukohara, Toru, Yoshimura, Kiyoshi, Imamura, Chiyo K, Miura, Sakiko, Yamochi, Toshiko, Kawabata, Hidetaka, Yasojima, Hiroyuki, Tomioka, Nobumoto, Yoshimura, Kenichi, Takano, Toshimi

“…BackgroundHormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies…”
Get full text

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer by Miyoshi, Yuichiro, Shien, Tadahiko, Ogiya, Akiko, Ishida, Naoko, Yamazaki, Kieko, Horii, Rie, Horimoto, Yoshiya, Masuda, Norikazu, Yasojima, Hiroyuki, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Tomioka, Nobumoto, Wanifuchi-Endo, Yumi, Hosoda, Mitsuchika, Doihara, Hiroyoshi, Yamashita, Hiroko

“…The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative…”
Get full text

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer by Ogiya, Akiko, Yamazaki, Kieko, Horii, Rie, Shien, Tadahiko, Horimoto, Yoshiya, Masuda, Norikazu, Inao, Touko, Hosoda, Mitsuchika, Ishida, Naoko, Osako, Tomofumi, Takahashi, Masato, Endo, Yumi, Miyoshi, Yuichiro, Yasojima, Hiroyuki, Tomioka, Nobumoto, Yamashita, Hiroko

“…Background Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive,…”
Get full text

Safety and Tolerance of Dose-Dense Epirubicin and Cyclophosphamide (EC) with Pegfilgrastim for Japanese Patients with Early Breast Cancer by Watanabe, Kenichi, Sato, Masako, Yamamoto, Mitsugu, Ikarashi, Mayuko, Hagio, Kanako, Tomioka, Nobumoto, Tamaki, Shinya, Takahashi, Yumi, Takahasi, Masato

“…With the approval of pegfilgrastim, the use of dose-dense epirubicin and cyclophosphamide (EC) for breast cancer has become acceptable in Japan. Thus, we aimed…”
Get more information

Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line by OHIRA, Miki, KAGEYAMA, Hajime, TOMIOKA, Nobumoto, SAKIYAMA, Shigeru, KANEKO, Yasuhiko, TOYODA, Atsushi, HATTORI, Masahira, SAKAKI, Yoshiyuki, OHKI, Misao, HORII, Akira, SOEDA, Eiichi, INAZAWA, Johji, MIHARA, Motohiro, SEKI, Naohiko, KUMA, Hidekazu, NOZAWA, Iwao, NAKAGAWARA, Akira, FURUTA, Shigeyuki, MACHIDA, Taiichi, SHISHIKURA, Tomotane, TAKAYASU, Hajime, ISLAM, Ashraful, NAKAMURA, Yohko, TAKAHASHI, Masato

“…Loss of heterozygosity of the distal region of chromosome 1p where tumor suppressor gene(s) might harbor is frequently observed in many human cancers including…”
Get full text

P66-6 Efficacy of everolimus in HR+ HER2- metastatic breast cancer patients after progression on CDK4/6 inhibitors by Watanabe, Kenichi, Kuwahara, Sayuri, Tachikawa, Hanae, Maeda, Hideki, Yamamoto, Mitsugu, Tomioka, Nobumoto, Takahashi, Masato

Get full text

AI-based quantification of TILs using hematoxylin and eosin and immunohistochemistry-stained slides in triple-negative breast cancer by Kobayashi, Takuma, Tomioka, Nobumoto, Hatanaka, Kanako C, Konishi, Teppei, Grynkiewicz, Mateusz, Komura, Daisuke, Ishikawa, Shumpei, Watanabe, Kenichi, Takahashi, Masato, Hatanaka, Yutaka

“…e13608 Background: The importance of accurately understanding the status of tumor-infiltrating lymphocytes (TILs) in the preoperative chemotherapy context, for…”
Get full text

Deep learning-based quantitative assessment of tumor-infiltrating lymphocytes from hematoxylin and eosin-stained slides in triple-negative breast cancer: A prognostic study by Kobayashi, Takuma, Hatanaka, Kanako C, Tomioka, Nobumoto, Konishi, Teppei, Grynkiewicz, Mateusz, Komura, Daisuke, Ishikawa, Shumpei, Watanabe, Kenichi, Takahashi, Masato, Hatanaka, Yutaka

“…553 Background: Tumor-infiltrating lymphocytes (TILs) are pivotal in predicting responses to preoperative chemotherapy in triple-negative breast cancer. Yet,…”
Get full text

Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial) by Iwamoto, Takayuki, Niikura, Naoki, Watanabe, Kenichi, Takeshita, Takashi, Kikawa, Yuichiro, Kobayashi, Kokoro, Iwakuma, Nobutaka, Okamura, Takuho, Kobayashi, Takayuki, Katagiri, Yuriko, Kitada, Masahiro, Tomioka, Nobumoto, Miyoshi, Yasuo, Shigematsu, Hideo, Miyashita, Minoru, Ishiguro, Hiroshi, Masuda, Norikazu, Saji, Shigehira

“…Purpose This study aimed to determine whether the 21-Gene Breast Recurrence Score® assay from primary breast tissue predicts the prognosis of patients with…”
Get full text

Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation by Takada, Shinya, Maeda, Hideki, Umehara, Kengo, Kuwahara, Sayuri, Yamamoto, Mitsugu, Tomioka, Nobumoto, Takahashi, Masato, Watanabe, Kenichi, Hashishita, Hirokazu

“…The association between abemaciclib dose reduction and treatment adherence is not clear. In this study, we examined real-world data of Japanese patients with…”
Get full text

Risk Factors for Eribulin-induced Severe Neutropenia in Patients With Recurrent Breast Cancer by Takada, Shinya, Hosokawa, Yoshihiro, Umehara, Kengo, Kimura, Yuta, Fukai, Yuta, Shikishima, Karin, Yamamoto, Mitsugu, Maeda, Hideki, Tomioka, Nobumoto, Watanabe, Kenichi, Hashishita, Hirokazu

“…Eribulin is an effective chemotherapeutic agent for advanced and metastatic breast cancer. However, severe neutropenia occurs in 30-40% of patients and…”
Get full text

Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region by Tomioka, Nobumoto, Hatanaka, Kanako C., Okuyama, Dai, Watanabe, Ken-ichi, Yamamoto, Mitsugu, Maeda, Hideki, Tachikawa, Hanae, Kuwahara, Sayuri, Shimizu, Ai, Suzuki, Hiroaki, Hatanaka, Yutaka, Takahashi, Masato

Get full text

Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence by Miyoshi, Yuichiro, Shien, Tadahiko, Ogiya, Akiko, Ishida, Naoko, Yamazaki, Kieko, Horii, Rie, Horimoto, Yoshiya, Masuda, Norikazu, Yasojima, Hiroyuki, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Tomioka, Nobumoto, Endo, Yumi, Hosoda, Mitsuchika, Doihara, Hiroyoshi, Miyoshi, Shinichiro, Yamashita, Hiroko

“…The significance of the expression of aldehyde dehydrogenase 1 (ALDH1), a cancer stem cell marker, for predicting the recurrence of estrogen receptor…”
Get full text

Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes by Watanabe, Kenichi, Hagio, Kanako, Baba, Motoi, Ikarashi, Mayuko, Sato, Masako, Tomioka, Nobumoto, Takahashi, Masato

Get full text

Evaluation of Pertuzumab Treatment for Metastatic Breast Cancer in a Retrospective Single Institution Study by Yamamoto, Mitsugu, Watanabe, Kenichi, Tomioka, Nobumoto, Sato, Masako, Maeda, Hideki, Tachikawa, Hanae, Terai, Sayuri, Takahashi, Masato

Get full text